HTDS Medical Information

HTDS Medical has found the best way to increase shareholder value, separate and apart from the operating performance of operating subsidiaries, by spinning off and distributing shares of its wholly owned subsidiaries in the form of a special dividend to the Company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of HTDS Medical into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors. The company is in the process of merging with a China based medical company. We are also continuing our negotiations with an East European medical company whose primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.